Undoubtedly, India is the epicentre for vaccine manufacturing in the world. With many top vaccine giants supplying basic and advanced vaccines to nearly 150 countries, India, over the years, has emerged as the global vaccines hub. A report titled "Indian Vaccine Market Report and Forecast 2017-2022", says that the Indian vaccine market reached a value of around INR 59 Billion in 2016, growing at a CAGR of nearly 18% during 2009-2016. Indian vaccine industry with many state-of-the-art manufacturing facilities has earned India the recognition of having the largest global capacity for WHO prequalified vaccine manufacturing. Along with other factors, increased public awareness about vaccination and public immunization programs, coupled with government support to develop new vaccine act as key factors driving India’s vaccine industry.
Speaking to BioSpectrum Asia Magazine, Dr K Anand Kumar, Managing Director Indian Immunologicals Ltd & Director Pristine Biologicals (NZ) Ltd, said that with many lucrative factors anchoring the vaccine business, the current market of USD 1 billion could easily double to USD 2 billion in less than 5 years.
With a robust R&D pipeline developing vaccines against Classical Fever, Goat pox and Infectious Bovine Rhinotracheitis (IBR )Indian Immunologicals Limited (IIL) is India’s top vaccine manufacturing company which has presence both in Animal and Human vaccine markets.
IIL recently inked an MOU with INTA and Littoral Biologics of Argentina for transfer of technology for Bovine Parasitic vaccines in India. The deal will help IIL address this unmet need to control haemoprotozoan diseases transmitted by ticks in India and prevent loss of productivity in cattle.
In an interaction with Dr K Anand Kumar:
What according to you are upcoming trends in India’s vaccine market?
The Indian vaccine market can be broadly be classified as the Domestic Trade Market (DTM) and Government Business (GB) including UIP supplies. There is also an Export Market that the Indian manufacturers tap into supplying to UNICEF/GAVI by way of WHO PQ. The total market size for vaccines would be about a billion USD. Value wise the Export Market would be 50%, the trade market would be around 30% and the GB would be around 20%. There is growing awareness on preventive measures to fight against diseases in India. While Indian pharma industry is growing at 10% over the past year, the vaccine industry is growing at 25% between 2011- 2015. The upcoming trends in the market space include the following:
Increased uptake of new generation vaccines such as Pneumococcal conjugate vaccine, Varicella vaccine, Rotavirus vaccine, HPV, typhoid conjugate vaccine in the trade segment.
- Increased uptake of multivalent vaccines such as the Hexavalent vaccine.
- Large scale introduction of vaccines such as Pentavalent vaccine, inactivated polio vaccine, MR vaccine by the Government Business.
- Ready to use presentation such as Prefilled syringes.
- Needle free delivery.
- Independent clinics for vaccination purposes only.
- More and more focus on vaccines for Zoonotic diseases.
- More and more recombinant vaccines will be seen in the animal vaccine segment.
Please elaborate on some on the key drivers of India’s vaccine businesses?
There is more awareness now about the ability of vaccines to prevent disease than ever before. The Swach Bharat Mission also has helped bring in sense of good hygiene and cleanliness. It is inevitable that the government in the coming years will spend significant amount on Healthcare. Similarly the per capita government spend on routine immunization is also going to increase with the addition of vaccines such as Pneumococcal conjugate vaccine, inactivated polio vaccine etc. Several programmes including the India New born Action Plan launched in 2014 will increase the uptake of vaccines to prevent death below the age of 5. This will drive more volume.
The educated and growing middle class segment is vary of the benefits of vaccination and will ensure their children will get vaccinated to as many preventable diseases as possible.
Th...
(All Rights Reserved)